On November 10, 2022 TAE Life Sciences (TLS), a biological-targeted radiation therapy company developing next-generation boron neutron capture therapy (BNCT), reported a partnership with HDX Corporation (HDX) to bring TLS’s targeted radiation therapy to South Korea for the treatment of difficult-to-treat cancers, such as brain, head and neck cancers and melanoma (Press release, TAE Life Sciences, NOV 10, 2022, View Source [SID1234623786]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Under the terms of the partnership, HDX, a premier distributor of radiation therapy medical equipment and clinical services based in Seoul will provide primary sales, marketing, services, and distribution channel for the TLS Alphabeam System, including radiation oncology equipment, software and boron target drugs in South Korea.
"I am very pleased to announce the partnership with HDX. HDX is the ideal partner that has deep relationships with major hospitals in South Korea, a strong sales organization, and the established capability to provide clinical and technical support to our future customers," said Bruce Bauer, PhD, CEO of TAE Life Sciences. "South Korea has a strong history in adoption of advanced radiation therapy solutions. Our cutting-edge Alphabeam System provides both an in-hospital neutron source technology and the boron target pharmaceuticals that are required for a comprehensive BNCT system."
TLS will provide support and training to HDX and intends to work with HDX to develop a local-language training and clinical education base in the future.
"Our partnership with TAE Life Sciences underscores the global expansion of BNCT as a unique cancer treatment for difficult-to-treat cancers," Sang-Jin Jung, CEO of HDX. "We are excited to work alongside TAE Life Sciences to provide this personalized radiation therapy in South Korea."
About BNCT
BNCT is a combination treatment based on the reaction that occurs when a non-toxic compound containing boron-10 is irradiated with a low-energy neutron beam. BNCT differs radically from other radiation therapy and shows promise in becoming the next-generation cancer treatment. Research has shown BNCT has the capability of killing cancer cells that are resistant to traditional radiation therapy with limited harm to healthy tissue. Current advances in both neutron radiation technology and medicinal boron drug targeting are enabling BNCT’s potential to improve patient care while also improving treatment economics. To date, approximately 2,000 patients have been treated with BNCT at research sites worldwide.